Correlation Between Inozyme Pharma and Exelixis

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Exelixis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Exelixis into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Exelixis, you can compare the effects of market volatilities on Inozyme Pharma and Exelixis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Exelixis. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Exelixis.

Diversification Opportunities for Inozyme Pharma and Exelixis

-0.83
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Inozyme and Exelixis is -0.83. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Exelixis in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Exelixis and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Exelixis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Exelixis has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Exelixis go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Exelixis

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Exelixis. In addition to that, Inozyme Pharma is 1.13 times more volatile than Exelixis. It trades about -0.79 of its total potential returns per unit of risk. Exelixis is currently generating about 0.33 per unit of volatility. If you would invest  2,832  in Exelixis on August 24, 2024 and sell it today you would earn a total of  651.00  from holding Exelixis or generate 22.99% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Inozyme Pharma  vs.  Exelixis

 Performance 
       Timeline  
Inozyme Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Exelixis 

Risk-Adjusted Performance

16 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Exelixis are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical and fundamental indicators, Exelixis disclosed solid returns over the last few months and may actually be approaching a breakup point.

Inozyme Pharma and Exelixis Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inozyme Pharma and Exelixis

The main advantage of trading using opposite Inozyme Pharma and Exelixis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Exelixis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exelixis will offset losses from the drop in Exelixis' long position.
The idea behind Inozyme Pharma and Exelixis pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Other Complementary Tools

Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital